PT Pyridam Farma Tbk (PYFA) Fair Value & Analysis

Healthcare · ID · Market cap 2.4T IDR

Below-average quality, and screening another 82% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (58.02 IDR). The favourable scenario is already priced in.
• Weak quality (15/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (29.01 IDR to 58.02 IDR) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range 87.00 IDR – 1,400 IDR · fair‑value band 29.01 IDR – 58.02 IDR · the 218.00 IDR price screens above the 38.87 IDR fair value. Dashed = 300-day average. As of Jul 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PT Pyridam Farma Tbk (PYFA) currently trades at 218.00 IDR, while our model-based Fair Value estimate is 38.87 IDR, implying the stock looks roughly 82.2% overvalued today. The Quality Score stands at 15/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, PT Pyridam Farma Tbk generated revenue of 2.8T IDR at a net margin of -13.0%. Revenue grew 11.8% year over year. It earns a return on equity of -38.7%. Net debt stands at 4.7T IDR. Fundamentals as of Jul 16, 2026

Our scenario range runs from 29.01 IDR (bear case) to 58.02 IDR (bull case); at 218.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 38% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -82%, PYFA screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments.

Full company description

PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper. The company also provides skin care and beauty products; medical support products; and other consumer health products in the form of syrups, tablets, and capsules; sterile and injection; and sanitizers and antiseptics. In addition, it offers antiseptic solutions, betadine antiseptic skin cleansers, Betadine Vaginal Douche, Cold defense nasal and throat sprays, feminine hygiene, Guardix SG, Mouthwash and Gargle, Salep antiseptic products. PT Pyridam Farma Tbk was founded in 1976 and is headquartered in Jakarta Selatan, Indonesia. PT Pyridam Farma Tbk operates as a subsidiary of Rejuve Global Investment Pte. Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PT Pyridam Farma Tbk reported revenue of 2.8T IDR in FY2025 versus 631B IDR in FY2021, a compound +44.6%/yr. Reported net income was −380B IDR in FY2025.

PYFA screens 82% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.